Stoke Therapeutics' Series A Round

Stoke Therapeutics raised a round of funding on January 04, 2018. Investors include Apple Tree Partners.

Stoke Therapeutics is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases. Stoke's NextGen RNAseq yields wh…

Articles about Stoke Therapeutics' Series A Round: